MyMD Pharmaceuticals Files 8-K Amendment
Ticker: QCLS · Form: 8-K/A · Filed: Mar 26, 2024 · CIK: 1321834
| Field | Detail |
|---|---|
| Company | Mymd Pharmaceuticals, Inc. (QCLS) |
| Form Type | 8-K/A |
| Filed Date | Mar 26, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, corporate-governance, filing-update
TL;DR
MyMD Pharma (MYMD) filed an 8-K/A amendment on March 26th for events on March 4th, updating bylaws and financials.
AI Summary
MyMD Pharmaceuticals, Inc. filed an amendment (Amendment No. 1) to its Form 8-K on March 26, 2024, regarding events that occurred on March 4, 2024. This amendment pertains to changes in its Articles of Incorporation or Bylaws and includes financial statements and exhibits. The company was formerly known as Akers Biosciences, Inc., with a name change occurring on April 13, 2017.
Why It Matters
This filing indicates an update to the company's foundational legal documents and financial reporting, which could signal corporate restructuring or significant operational changes.
Risk Assessment
Risk Level: low — This is a procedural amendment to a previous filing, not indicating new material events or financial distress.
Key Players & Entities
- MyMD Pharmaceuticals, Inc. (company) — Registrant
- Akers Biosciences, Inc. (company) — Former company name
- March 4, 2024 (date) — Earliest event date
- March 26, 2024 (date) — Filing date
- April 13, 2017 (date) — Date of former company name change
FAQ
What specific changes were made to the Articles of Incorporation or Bylaws in this amendment?
The filing is an amendment to a Form 8-K and indicates changes related to 'Amendments to Articles of Incorporation or Bylaws' and 'Financial Statements and Exhibits', but the specific details of the changes are not provided in the excerpt.
What was the original event reported on March 4, 2024, that necessitated this amendment?
The excerpt states that March 4, 2024, is the date of the earliest event reported, but does not specify the nature of that original event.
Why is this filing classified as an 8-K/A (Amendment) rather than a new 8-K?
It is an 8-K/A because it is an amendment to a previously filed Form 8-K, indicating corrections or additions to information previously reported.
What is the significance of the company formerly being known as Akers Biosciences, Inc.?
This indicates a corporate name change occurred, with the most recent former name change from Akers Biosciences, Inc. to MyMD Pharmaceuticals, Inc. happening on April 13, 2017.
What is the primary business of MyMD Pharmaceuticals, Inc. according to the SIC code?
The Standard Industrial Classification (SIC) code provided is 2835, which corresponds to 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES'.
Filing Stats: 738 words · 3 min read · ~2 pages · Grade level 11.1 · Accepted 2024-03-26 16:30:43
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share MYMD The Nasdaq Capital M
Filing Documents
- form8-ka.htm (8-K/A) — 41KB
- ex3-3.htm (EX-3.3) — 12KB
- 0001493152-24-011310.txt ( ) — 227KB
- mymd-20240304.xsd (EX-101.SCH) — 3KB
- mymd-20240304_lab.xml (EX-101.LAB) — 33KB
- mymd-20240304_pre.xml (EX-101.PRE) — 22KB
- form8-ka_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MYMD PHARMACEUTICALS, INC. Date: March 26, 2024 By: /s/ Ian Rhodes Ian Rhodes Chief Financial Officer